文献速递浆细胞疾病

CEPHEUS研究扩展MRD分析:D-VRd在不适合或推迟移植的新诊断多发性骨髓瘤中的疗效

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.
PubMed 文献 · Blood Adv · 2026-01-01

CEPHEUS是一项3期随机研究,在不适合或推迟移植的新诊断多发性骨髓瘤患者中比较D-VRd与VRd。中位随访58.7个月,D-VRd组总体MRD阴性率(10⁻⁵和10⁻⁶阈值)及持续MRD阴性率均显著高于VRd组,且D-VRd带来更深更持久的缓解和意向治疗人群PFS改善。

要点

  • D-VRd较VRd显著提高10⁻⁵阈值总体MRD阴性率(60.9% vs 39.4%)。
  • D-VRd持续≥12个月MRD阴性率在10⁻⁵阈值为49.2% vs 27.3%。
  • D-VRd成为不适合/推迟移植NDMM的新标准治疗。

核心结论

  • D-VRd在不适合或推迟移植的新诊断多发性骨髓瘤患者中,较VRd显著提高总体、持续及 landmark MRD阴性率,并改善意向治疗人群的PFS,成为新的标准治疗。

研究设计与样本

  • 3期CEPHEUS研究随机入组395例不适合或推迟移植的新诊断多发性骨髓瘤患者(D-VRd组197例,VRd组198例)。
  • MRD采用二代测序评估,总体MRD阴性定义为达到完全缓解或更好且MRD阴性,主要终点为10⁻⁵阈值。

临床怎么用

  • 对于不适合或推迟移植的新诊断多发性骨髓瘤患者,可考虑D-VRd方案以提高MRD阴性率和PFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 CEPHEUS study, D-VRd (daratumumab/bortezomib/lenalidomide/dexamethasone) increased overall minimal residual disease (MRD)-negativity rates vs VRd in patients who were transplant ineligible/deferred with newly diagnosed multiple myeloma (NDMM). We present an expanded MRD analysis of CEPHEUS. Patients who were transplant-ineligible or deferred transplant as initial therapy were randomized to D-VRd or VRd. Overall MRD negativity (next-generation sequencing) was defined as the proportion of patients achieving complete response or better and MRD-negative status assessed at 10-5 (primary end point) and 10-6 thresholds. In total, 395 patients were randomized (D-VRd, n = 197; VRd, n = 198). With 58.7-months median follow-up, overall MRD-negativity rates were significantly higher with D-VRd vs VRd (10-5: 60.9% vs 39.4%; odds ratio [OR], 2.37; 95% confidence interval [CI], 1.58-3.55; P< .0001; 10-6: 46.2% vs 27.3%; OR, 2.24; 95% CI, 1.48-3.40; P = .0001). Sustained MRD negativity (≥12 months) was significantly higher with D-VRd vs VRd (10-5: 49.2% vs 27.3%; 10-6: 34.0% vs 16.2%; each P< .0001), with similar benefits at ≥24 and ≥36 months. MRD-negativity rates were higher at all prespecified time points and cumulatively with D-VRd. Among patients who achieved MRD negativity, progression-free survival (PFS) trended in favor of D-VRd vs VRd (10-5: hazard ratio, 0.61; 95% CI, 0.35-1.06; P = .0755; 10-6: 0.66; 95% CI, 0.31-1.41; P = .2811). Responses with D-VRd were deeper and more durable vs VRd, with increased overall, sustained, and landmark MRD-negativity rates, translating into improved overall PFS with D-VRd vs VRd (intent-to-treat), with potential to improve PFS even among patients with MRD negativity. D-VRd is therefore a new standard-of-care treatment for transplant-ineligible/transplant-deferred NDMM. This trial was registered at www.clinicaltrials.gov as NCT03652064.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zweegman S, Facon T, Hungria V, et al. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood Adv. 2026. PMID: 42234958. doi:10.1182/bloodadvances.2026019937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。